Literature DB >> 12746549

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.

Kanchan Anand1, John Ziebuhr, Parvesh Wadhwani, Jeroen R Mesters, Rolf Hilgenfeld.   

Abstract

A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746549     DOI: 10.1126/science.1085658

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  659 in total

1.  Current status of severe acute respiratory syndrome in China.

Authors:  Qing-He Nie; Xin-Dong Luo; Jian-Zhong Zhang; Qin Su
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  Small molecules targeting severe acute respiratory syndrome human coronavirus.

Authors:  Chung-Yi Wu; Jia-Tsrong Jan; Shiou-Hwa Ma; Chih-Jung Kuo; Hsueh-Fen Juan; Yih-Shyun E Cheng; Hsien-Hua Hsu; Hsuan-Cheng Huang; Douglass Wu; Ashraf Brik; Fu-Sen Liang; Rai-Shung Liu; Jim-Min Fang; Shui-Tein Chen; Po-Huang Liang; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

3.  A genomic analysis of rat proteases and protease inhibitors.

Authors:  Xose S Puente; Carlos López-Otín
Journal:  Genome Res       Date:  2004-04       Impact factor: 9.043

4.  Temperature-sensitive mutants and revertants in the coronavirus nonstructural protein 5 protease (3CLpro) define residues involved in long-distance communication and regulation of protease activity.

Authors:  Christopher C Stobart; Alice S Lee; Xiaotao Lu; Mark R Denison
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Biocrystallography: past, present, future.

Authors:  Richard Giegé; Claude Sauter
Journal:  HFSP J       Date:  2010-04-22

6.  Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Authors:  Sankar Manepalli; Laura M Geffert; Christopher K Surratt; Jeffry D Madura
Journal:  J Chem Inf Model       Date:  2011-09-02       Impact factor: 4.956

Review 7.  Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19.

Authors:  Nikhil Bhalla; Yuwei Pan; Zhugen Yang; Amir Farokh Payam
Journal:  ACS Nano       Date:  2020-06-26       Impact factor: 15.881

8.  Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity.

Authors:  Christopher C Stobart; Nicole R Sexton; Havisha Munjal; Xiaotao Lu; Katrina L Molland; Sakshi Tomar; Andrew D Mesecar; Mark R Denison
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

9.  3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.

Authors:  Jinzhi Tan; Shyla George; Yuri Kusov; Markus Perbandt; Stefan Anemüller; Jeroen R Mesters; Helene Norder; Bruno Coutard; Céline Lacroix; Pieter Leyssen; Johan Neyts; Rolf Hilgenfeld
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1.

Authors:  Qi Zhao; Shuang Li; Fei Xue; Yilong Zou; Cheng Chen; Mark Bartlam; Zihe Rao
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.